Who are we?
שורשיה של טבע נטועים עמוק באדמתה של ישראל החל משנת 1901 בירושלים. אז נכתב הפרק הראשון בהיסטוריה הארוכה והייחודית של החברה, אשר הפכה אט-אט מבית מסחר קטן לתרופות לחברה הגנרית הגדולה בעולם, המשפרת את בריאותם של מיליוני מטופלים בארץ ובעולם בכל יום.
Drugs Disributed by Abic Marketing Ltd, Israel
NSAID. Diclofenac Sodium 50 mg, 100 mg. SUPPS: 10. 2 supps. at night.
Rheumat. arthr., osteoarthr., low back pain,
other acute musculosk. disord. such as
periarthr., tendin., tenosynov., bursitis,
sprains, strains, dislocation, ankyl.
spondylitis, acute gout. Control of pain/
inflamm. in orthopedic, dental, and other
S.R. TABS: 20. 1 tab. dly.
Rheum. arthrit., other rheum. conds.
C/I: Hypersens. to the product. Active
gastr./ intest. ulcer, bleeding or perfor.
Active/ history of recur. peptic ulcer/
haemorrhage (>=2 distinct epis. of
proven ulcer./ bleeding). History of GI
bleeding/perfor., relating to prev. NSAID
tmt. Last trimester of pregn. Sev. hepatic
and renal failure. Establ. CHF (NYHA class
II-IV), isch. heart dis., periph. arter. dis.,
cerebrovasc. dis. Pts. in whom aspirin or
other NSAIDs have induc. sympt. of
asthma, acute rhinitis precipit. by
ibuprofen, urticaria, nasal polyps,
angioedema, bronchospasm, other
sympt. of allergic react. (anaphyl. react.
have occur. in such pts). Pts with sev.
heart failure. Tmt of peri-operative pain
in CABG surg.
Opioid. Fentanyl (as citrate) 200, 400, 600, 800, 1200, 1600 mcg/dose. COMPRESSED TAB. ON HANDLE
(lozenge): 30. Initial: 200 μg. To supply
only 6 x 200 μg and to use all units bef. incr. to higher dose. See lit. Unit to be
sucked, not chewed over 15 mins.
Discont: Grad. downward titrat.
Manage. breakthrough cancer pain in pts
16 and older with maligns. who are
already receiv. and tolerant to opioid ther.
for persist. cancer pain.
C/I: Post-op. pain, opioid non-tol.,
hypersens./intol. to fentanyl, anaphylax.
Bisphosphonate. Risedronate Sodium 150 mg. TABS.:1,2,3,4. Tab wkly. to be swallowed whole and not sucked or chewed in an upright position with glass of plain water, at least 30 mins. bef. first food, other medicine or drink (except water) of the day. Pts should not lie down for 30 mins aft. taking tab.
Tmt. of postmenopaus. osteoporosis. Prevent. of postmenopaus. osteoporosis
C/I: Hypersens. Hypocalcaem. Preg., lact.
Severe renal impair.(CrCl <30 ml/min).
Inabil. to stand or sit upright for at least 30 min.
Thiazolidinediones. Pioglitazone 15, 30, 45 mg. TABS.: 15 mg, 30 mg, 45
mg x 28.
Once dly with or w/o food. Initial treat.:
15 mg or 30 mg once dly; may be
increased up to 45 mg once dly. May
be used in combination with insulin.
See lit. Elderly: No dose adjustment is
necessary. Renal impair.ent: No dose
adjustment is necessary in pts. with
impaired renal func. (CLcr > 4 ml/min) Not to be used in dialysed pts. Hepatic
impair.ent: should not be used in pts.
With hepatic impair.ent Paediatric: Not
to be used in children and adolescents
under 18 yrs of age.
As second or third line treatment of type 2
diabetes mellitus: as monotherapy: in
adult patients (particularly overweight
patients) inadequately controlled by diet
and exercise for whom metformin is
inappropriate because of
contraindications or intolerance as dual
oral therapy in combination with
metformin, in adult patients (particularly
overweight patients) with insufficient
glycaemic control despite maximal
tolerated dose of monotherapy with
metformin; with a sulphonylurea, only in
adult patients who show intolerance to
metformin or for whom metformin is
contraindicated, with insufficient
glycaemic control despite maximal
tolerated dose of monotherapy with a
sulphonylurea. As triple oral therapy in
combination with: metformin and a
sulphonylurea, in adult patients
(particularly overweight patients) with
insufficient glycaemic control despite dual
oral therapy.Pioglitazone is also indicated
for combination with insulin in type 2
diabetes mellitus adult patients with
insufficient glycaemic control on insulin
for whom metformin is inappropriate
because of contraindications or
intolerance.After initiation of therapy with
pioglitazone, patients should be reviewed
after 3 to 6 months to assess adequacy of
response to treatment (e.g. reduction in
HbA1c). In patients who fail to show an
adequate response, pioglitazone should
be discontinued. In light of potential risks
with prolonged therapy, prescribers should
confirm at subsequent routine reviews
that the benefit of pioglitazone is
C/I: Hypersens. to product; cardiac
failure or history of cardiac failure (NYHA
stages I to IV); hepatic impair.ent;
diabetic ketoacidosis; current bladder
cancer or a history of bladder cancer;
uninvestigated macroscopic haematuria.
CGRP Antagonist, Monoclonal Antibody. Fremanezumab 225 mg. PREFILLED SYR (sol. for SC inj.): 1,3× 1.5ml. Tmt. is intended for pts. with at least 4 migraine days/month when initiat. tmt. with fremanezumab.
Two dosing options are available:
225 mg once mnthly. (mnthly. dosing) or 675 mg every three mnths. (quarterly dosing).
When switching dosing regimens, the first dose of the new regimen should be admin. on the next scheduled dosing date of the prior regimen.
When initiat. tmt. with fremanezumab, concom. migraine prevent. tmt. may be continued if consid. necessary by the prescriber.
The tmt. benefit should be assessed within 3 mnths. after init. of tmt. Any further decision to continue tmt. should be taken on an individ. pt. basis. Evaluation of the need to continue tmt. is recomm. regularly thereafter.
Missed dose: If a fremanezumab inject. is missed on the planned date, dosing should resume as soon as possible on the indicated dose and regimen. A double dose must not be admin. to make up for a missed dose.
Indicat. for prophylaxis of migraine in adult. who have at least 4 migraine days per month.
Calcitonin gene-related peptide (CGRP) antagonists.. Fremanezumab 225 mg. PRE-FILL. SYR. (Sol.for S.C. inj.):1, 3×1.5ml.
PRE-FILL PEN (Sol.for S.C. inj.): 1, 3×1.5 ml. Tmt. is intend. for pts. with at least 4 migraine days per month when initiat. tmt. with fremanezumab.
Two dosing options are avail.:
225 mg once mnthly 675 mg every 3 mnths. (quarter. dosing)
When switch. dosing regimens, the 1st dose of the new regimen should be admin. on the next scheduled dosing date of the prior regimen.
When initiating treatment with fremanezumab, concom. migraine prevent. tmt. may be contin. if consid. necessary by the prescriber .
The tmt. benefit should be assessed within 3 mnths. after initiat. of tmt. Any further decision to cont. tmt. should be taken on an individ. pt. basis. Evaluat. of the need to cont. tmt. is recomm. regularly thereafter.
Missed dose - dosing should resume as soon as possible on the indicat. dose and regimen. A double dose must not be admin. to make up for a missed dose.
Indicated for prophylax. of migraine in adults who have at least 4 migraine days per
C/I: Hypersens. react. such as rash, pruritus, urticaria and swell. have been reported uncommon. with fremanezumab. Most react. were reported from within hrs. to one month after admin. and were mild – moder., but some led to discount. or required corticosteroid tmt. If a hypersens. reaction occurs, discount. of fremanezumab admin. should be consid.and appropriate ther. should be initiated.